Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 2Advanced Solid Tumors 1

Interventions

pembrolizumab 42Carboplatin 38Cisplatin 34Paclitaxel 27Pemetrexed 23Gemcitabine 23Nivolumab 22Dexamethasone 17Ipilimumab 16Rituximab 15Fluorouracil 14Capecitabine 14Docetaxel 13trastuzumab deruxtecan 12durvalumab 12atezolizumab 12Cyclophosphamide 12Trastuzumab 11Lenalidomide 11olaparib 10130-nm albumin-bound paclitaxel 10Prednisone 9venetoclax 8daratumumab 8Oxaliplatin 8Cytarabine 8Bortezomib 8Bevacizumab 8zanubrutinib 7Vinorelbine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has announcements × PM 01183 × Clear all
NCT05091567 2026-03-10

IMforte

Hoffmann-La Roche

Phase 3 Active not recruiting
660 enrolled 23 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT05740566 2026-01-05

DeLLphi-304

Amgen

Phase 3 Active not recruiting
509 enrolled 11 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

PharmaMar

Phase 2 Completed
345 enrolled 34 charts 1 FDA
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡